SUBSCRIBE
SUBSCRIBE
News   Drug Development

NicOx SA Provides an Update on NCX 4016

June 18, 2007 | 
1 min read

NicOx S.A. (Eurolist: COX) today announced that NicOx and the US National Cancer Institute (NCI) have agreed to end an NCI-sponsored phase 1 trial studying the potential of NCX 4016 as a preventative treatment for colon cancer.

Clinical research Phase I Europe
MORE ON THIS TOPIC
3D illustration of an RNA molecule
Cardiovascular disease
Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Weigh scales on pink background, top view with space for text. Overweight concept
Weight loss
Kallyope Discreetly Drops Disappointing Data for Oral Obesity Candidate
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Regeneron logo on a light brown building
Lymphoma
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Gothenburg, Sweden – April 17, 2020: AstraZeneca in Gothenburg is one of three strategic global R&D centres in medicine. A big sign with the company logotype just outside the entrance.
Cancer
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
February 26, 2025
 · 
1 min read
 · 
Dan Samorodnitsky